Brandtree

United Therapeutics: brands it owns and its ownership tree

United Therapeutics (NASDAQ: UTHR) is a publicly listed company headquartered in Silver Spring, United States that owns 5 consumer brands.[1]

United Therapeutics is a US biotechnology company. Its 2025 Form 10-K reports sales of pulmonary arterial hypertension medicines and of Unituxin.

Company facts

Legal name
United Therapeutics Corporation
Headquarters
🇺🇸 Silver Spring, United States
Type
publicly listed company · all publicly listed company owners
Founded
1996
Tickers
NASDAQ: UTHR
Identifiers
SEC CIK 0001082554
Last verified
· 1 sources

Brands United Therapeutics owns

5 brands in 1 category.

Drug makers (5)

  • Adcirca

    Biotechnology · 🇺🇸 United States

  • Orenitram

    Biotechnology · 🇺🇸 United States

  • Remodulin

    Biotechnology · 🇺🇸 United States

  • Tyvaso

    Biotechnology · 🇺🇸 United States

  • Unituxin

    Biotechnology · 🇺🇸 United States

Full list of 5 brands with sources · Interactive ownership tree

Ownership structure

No company is recorded as controlling United Therapeutics.

Who owns the shares of United Therapeutics

Holders of more than 5% of the voting shares, as listed in United Therapeutics's proxy statement filed 29 April 2026. Shareholdings change daily; this is the position the filing reports.

HolderSharesShare of class
BlackRock, Inc.5,294,84412.5%
Avoro Capital Advisors LLC2,858,8886.8%
Martine Rothblatt2,867,2906.5%
Wellington Management Group LLP2,441,4925.8%

Financials and filings

United Therapeutics financial history

Headline figures from United Therapeutics's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2020–2025. Revenue moved from $1.48bn to $3.18bn, an average of 16.5% a year (calculated).

Fiscal year endedRevenueOperating incomeOperating marginNet incomeTotal assetsLong-term debtFiling
$3.18bn $1.49bn 46.9% $1.33bn $7.88bn — 10-K
$2.88bn $1.38bn 47.9% $1.2bn $7.36bn — 10-K
$2.33bn $1.18bn 50.9% $984.8m $7.17bn — 10-K
$1.94bn $979.7m 50.6% $727.3m $6.04bn — 10-K
$1.69bn $555.9m 33.0% $475.8m $5.17bn — 10-K
$1.48bn $593.6m 40.0% — $4.62bn — 10-K

Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.

United Therapeutics SEC filings

The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.

Annual reports

Proxy statements

Recent current and quarterly reports

FiledFormWhat it declares
8-KResults of operations and financial condition
10-QQuarterly report
8-KOther events
8-KOther events
8-KEntry into a material agreement; Regulation FD disclosure
8-KResults of operations and financial condition
10-QQuarterly report
8-KDeparture or appointment of directors or officers; Regulation FD disclosure
8-KDeparture or appointment of directors or officers; Results of a shareholder vote
8-KResults of operations and financial condition
10-QQuarterly report
8-KOther events
8-KEntry into a material agreement; Regulation FD disclosure
8-KRegulation FD disclosure

United Therapeutics in the global legal-entity registry

The Global Legal Entity Identifier Foundation (GLEIF) keeps an open register of legal entities. Each entity reports its own parents. We show it as a cross-check on the ownership recorded on this page, which is built from filings.

Legal entity identifier (LEI)
5299005C4HZL4UWROC14
Registered name
UNITED THERAPEUTICS CORPORATION (US)
Registration status
Lapsed · record updated 10 November 2021
Parent
None named: it reports that it has no parent that consolidates its accounts.
Retrieved
· GLEIF record (JSON)

Frequently asked questions

What brands does United Therapeutics own?

United Therapeutics owns 5 consumer brands tracked here, including Orenitram, Remodulin, Unituxin, Adcirca and Tyvaso.

Is United Therapeutics an American company?

Yes. United Therapeutics is headquartered in Silver Spring, United States and was founded in 1996.

Who owns United Therapeutics?

United Therapeutics is a publicly listed company owned by its shareholders; it trades as UTHR on the NASDAQ.

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] United Therapeutics Corporation Annual Report on Form 10-K filed 2026-02-25 — SEC EDGAR, SEC Form 10-K, published 25 February 2026; retrieved 8 November 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.